PhRMA

03/08/2026

China wants to become the next center of medical innovation and progress.

The way the United States wins this race is by remaining the best place in the world to invest in and manufacture new medicines.

We should protect what is working in our system and reform the parts that add costs without adding value to patients. We must also reject price controls that would harm innovation and put us further behind.

03/06/2026

"Approval is a milestone… but it’s not the end of the road."

Pamela K. Gavin, CEO of NORD, highlights a critical truth: a treatment’s value is only realized when it reaches the patient.

For those living with rare and progressive conditions, any delay in care can be a big deal. Unexpected hurdles, like restrictive provider networks and inappropriate prior authorization can slow down or prevent timely access to medicines. Patients shouldn’t have to wait.

03/05/2026

Cell and gene therapies are transforming how we prevent and fight disease by targeting illness at the cellular and genetic level and offering the potential for long-lasting or even curative effects, often after a single administration.

As of January 2026, there are 25 approved cell and gene therapies, including 9 cancer therapies and 7 CAR T-cell therapies.

Yet access challenges remain. Just 1 in 10 eligible Medicare fee-for-service patients is receiving

CAR T-cell therapy due to systemic barriers like limited treatment centers, inadequate Medicare reimbursement and coverage restrictions.

To ensure patients can realize the benefits of these life-changing treatments, our health care system must evolve.

Read PhRMA’s Future of Medicine report by going to PhRMA.org/futureofmedicine and watch the full video here: https://www.youtube.com/watch?v=nrDDQlr2-rQ

03/04/2026

For more than 40 years, the United States has led the world in biopharmaceutical research, development and manufacturing.
But this leadership is not guaranteed. Today, China has the fastest growing biopharmaceutical pipeline in the world.

One example? China now leads the world in ongoing oncology clinical trials, with its share of oncology trial starts increasing from 5% to 39% between 2009 and 2024.

For the United States to maintain its position as the global leader in biopharmaceutical innovation, we must advance policies that foster a world-class innovation ecosystem here at home.

https://phrma.org/blog/harmful-u-s-policies-will-help-drive-china-s-global-leadership-in-biopharmaceutical-innovation

03/04/2026

“Ultimately, we have to be super competitive.”

FDA Commissioner Dr. Marty Makary highlights a startling reality: China is now a direct competitor for global biopharmaceutical leadership.

The U.S. must remain the world leader in medicine development. To stay ahead, we need smart policies that encourage risk-taking and innovation.

03/03/2026

America leads the world in developing new medicines.

Our biopharmaceutical innovators have delivered breakthroughs that help patients live longer and healthier lives while supporting jobs and economic growth nationwide.

That success is built on a system that rewards innovation and supports continued research and development.

To ensure the next generation of cures, we must protect the policies that make American leadership possible.

AmericaCures.com

03/02/2026

"For decades, it has been the case that the U.S. has been the world leader in medical innovation... that may be changing."

Learn more about why American biopharmaceutical leadership is at risk, and why that matters: AmericaCures.com

03/02/2026

Price controls like MFN don’t work—we've seen the results in other countries and the impact on patients is clear: fewer treatments and less access to lifesaving medicines. We shouldn’t make the same mistakes here.

To protect American patients and ensure access to affordable medicines, we should focus on:

- Addressing misaligned incentives that reward middlemen.
- Fixing the 340B hospital markup program.
- Ensuring other countries pay their fair share for innovation.

03/01/2026

NovartisUS announced plans to build a new 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, expanding the largest RLT manufacturing network in the U.S. and advancing its $23 billion commitment to U.S. investment.

The site will support next-generation cancer treatments, strengthen critical supply chains and create new jobs in bioengineering, advanced manufacturing, quality and operations.

Investments like this help ensure patients across the country have access to cutting-edge therapies while supporting economic growth in communities nationwide.

Read more:

Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor typesCompany broke ground on 4 new manufacturing and...

02/28/2026

Every year on February 28 we observe Rare Disease Day, a moment to recognize the hundreds of millions of people living with rare diseases around the world and to highlight the scientists, patients, caregivers and biopharmaceutical researchers working to transform lives.

Rare disease drug development is extremely challenging due to small patient populations, treatment complexities, regulatory challenges and economic uncertainty. Still, thanks to scientific progress and sustained investment, the biopharmaceutical industry has gained remarkable momentum in recent years.

Learn more about rare disease innovation:

02/27/2026

Biopharmaceutical companies are leveraging AI to help develop new medicines for patients with rare diseases and connect them with clinical trials faster and more efficiently.